Valitor

Valitor, Inc. is a biotechnology company focused on developing advanced therapeutic solutions for life-threatening and function-threatening diseases. Originating from UC Berkeley, Valitor's core technology platform allows the creation of multivalent protein (MVP) conjugates by attaching multiple bioactive molecules, such as camelid antibodies and cytokines, to single-chain, soluble biopolymers. This proprietary technology results in BioBetter products with enhanced pharmacological properties, offering superior efficacy, durability, and safety compared to existing treatments. Valitor primarily serves patients with mobility-threatening joint diseases, life-threatening cancers, and vision-threatening ophthalmic diseases. The company operates in the biopharmaceutical market, targeting healthcare providers and institutions. Valitor's business model revolves around the research, development, and commercialization of its proprietary therapeutic products, generating revenue through product sales and potential licensing agreements.

Keywords: biotechnology, MVP conjugates, camelid antibodies, cytokines, BioBetter, pharmacological properties, joint diseases, cancer therapy, ophthalmic diseases, biopharmaceutical.